Patent details
EP3813816 Title: USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS, (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID IN THE TREATMENT OF FRAGILE X SYNDROME OR FRAGILE X-ASSOCIATED TREMOR/ATAXIA SYNDROME
Basic Information
- Publication number:
- EP3813816
- PCT Application Number:
- US2019035934
- Type:
- European Patent Granted for LU
- Legal Status:
- Unitary Effect Registered
- Application number:
- EP198158925
- PCT Publication Number:
- WO2019236938
- First applicant's nationality:
- Translation Language:
- EPO Publication Language:
- English
- English Title of Invention:
- USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS, (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID IN THE TREATMENT OF FRAGILE X SYNDROME OR FRAGILE X-ASSOCIATED TREMOR/ATAXIA SYNDROME
- French Title of Invention:
- UTILISATION DE L'ACIDE (S)-3-AMINO-4-(DIFLUOROMÉTHYLÉNYL)CYCLOPENT-1-ÈNE-1-CARBOXYLIQUE ET DE COMPOSÉS APPARENTÉS, DE L'ACIDE (1S,3S)-3-AMINO-4-(DIFLUOROMÉTHYLIDÈNE)CYCLOPENTANE-1-CARBOXYLIQUE DANS LE TRAITEMENT DE LE SYNDROME DE L'X FRAGILE OU LE SYNDROME DE TREMBLEMENT/ATAXIE ASSOCIÉ À L'X FRAGILE
- German Title of Invention:
- VERWENDUNG VON (S)-3-AMINO-4-(DIFLUORMETHYLENYL)CYCLOPENT-1-EN-1-CARBONSÄURE UND VERWANDTEN VERBINDUNGEN, (1S,3S)-3-AMINO-4-(DIFLUORMETHYLIDEN)-CYCLOPENTAN-1-CARBONSÄURE ZUR BEHANDLUNG VON FRAGILES-X-SYNDROM ODER FRAGILES-X-ASSOZIIERTES TREMOR/ATAXIE-SYNDROM
- SPC Number:
Unitary Effect
- Unitary Effect Requested:
- Yes
- Unitary Effect Request Filing Date:
- 07/06/2023
- Link to UPP Register:
- European Patent Register
- Unitary Effect Request Withdrawal Date:
- Unitary Effect Status:
- Unitary Effect Registered
- Unitary Effect Acceptance Decision Date:
- 12/06/2023
- Unitary Effect Rejection Decision Date:
- Unitary Effect Date:
- 07/06/2023
- Unitary Effect Registration Date:
- 12/06/2023
- Unitary Effect Re-establishment of rights Filing Date:
- Unitary Effect Re-establishment of rights EPO Decision :
- Unitary Effect Re-establishment of rights EPO Decision Date:
- Explanatory Text UE:
- Safety Net Request Date:
- Safety Net Decision Date:
- Safety Net Decision Outcome:
- SPC Number:
Dates
- Filing date:
- 07/06/2019
- Grant date:
- 07/06/2023
- EP Publication Date:
- 05/05/2021
- PCT Publication Date:
- 12/12/2019
- Claims Translation Received Date:
- Translations Received Date (B1 EP Publication):
- Translations Received Date (B2 EP Publication):
- Translations Received Date (B3 EP Publication):
- Publication date:
- 07/06/2023
- EP B1 Publication Date:
- 07/06/2023
- EP B2 Publication Date:
- EP B3 Publication Date:
- Lapsed date:
- Expiration date:
- 07/06/2039
- Renunciation date:
- Revocation date:
- Annulment date:
Owner
- From:
- 31/05/2023
- Name:
- Ovid Therapeutics Inc.
- Address:
- 441 9th Avenue,, New York, NY 10001, United States (US)
Inventor
1
- Name:
- ABRAHAMS, Brett
- Address:
- United States (US)
2
- Name:
- DURING, Matthew
- Address:
- United States (US)
Priority
- Priority Number:
- 201862681913 P
- Priority Date:
- 07/06/2018
- Priority Country:
- United States (US)
Classification
- IPC classification:
- A61K 31/196; A61K 31/00; A61K 31/185; A61K 31/19; A61P 25/00;
Publication
European Patent Bulletin
1
- Issue number:
- 202323
- Publication date:
- 07/06/2023
- Description:
- Grant (B1)
2
- Issue number:
- 202328
- Publication date:
- 12/07/2023
- Description:
- Unitary Effect Request Receipt
3
- Issue number:
- 202328
- Publication date:
- 12/07/2023
- Description:
- Unitary Effect Request Acceptance
Annual Fees
- Annual Fee Due Date:
- Annual Fee Number:
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|